EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY
Objective: to study the association of ultrasound (US) remission criteria with the clinical and laboratory indicators of inflammatory activity, functional status, and X-ray changes in patients with rheumatoid arthritis (RA) during tocilizumab (TCZ) therapy.Subjects and methods. The trial included 36...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2013-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849773872320086016 |
|---|---|
| author | Rita Aleksandrovna Osipyants D E Karateev E Yu Panasyuk G V Lukina A V Smirnov S I Glukhova E N Aleksandrova A V Volkov E L Nasonov |
| author_facet | Rita Aleksandrovna Osipyants D E Karateev E Yu Panasyuk G V Lukina A V Smirnov S I Glukhova E N Aleksandrova A V Volkov E L Nasonov |
| author_sort | Rita Aleksandrovna Osipyants |
| collection | DOAJ |
| description | Objective: to study the association of ultrasound (US) remission criteria with the clinical and laboratory indicators of inflammatory activity, functional status, and X-ray changes in patients with rheumatoid arthritis (RA) during tocilizumab (TCZ) therapy.Subjects and methods. The trial included 36 patients with RA (meeting the 1987 American College of Rheumatology (ACR) criteria) who had received TCZ for 6 months. The authors made a clinical and laboratory assessment of RA activity (DAS28-CRP, and SDAI), functional impairments (HAQ index) and US verification of wrist joint synovitis (a Voluson-i device, GE, 4-13-MHz linear transducer) at baseline and 6 months after therapy. No signs of grey-scale (B-mode) and power Doppler (PD) synovitis (B = 0; PD = 0) or minimal B-mode synovitis, and not more one PD hypervascular signal (В ≤1; PD ≤1) were arbitrarily taken as US remission criteria. Destruction changes were evaluated by hand and foot X-ray using the Sharp method modified by van der Heijde (SHS).Results. After 6 months of therapy, about 80% of the patients in clinical remission retained moderate or significant synovitis, as evidenced by US studies. There were no clinical differences in clinical activity indices and functional impairments between the patients who were and were not in US remission (p > 0.05). The 12-month follow-up SHS score was significantly higher with the preservation of 6-month therapy signs of B-mode synovitis and PD hypervascularization (of not more than one signal) than that in US remission (p < 0.05). There was no relationship of X-ray progression to the clinical and functional statuses (p > 0.05).Conclusion. Subclinical synovitis is observed even in clinical remission of RA. Destruction progression is significantlyrelated to synovitis persistence, as shown by ultrasonography. |
| format | Article |
| id | doaj-art-e001308b61b545fcaff463d65cd7a6fb |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2013-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-e001308b61b545fcaff463d65cd7a6fb2025-08-20T03:01:55ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922013-12-0151550050610.14412/1995-4484-2013-15401275EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPYRita Aleksandrovna Osipyants0D E Karateev1E Yu Panasyuk2G V Lukina3A V Smirnov4S I Glukhova5E N Aleksandrova6A V Volkov7E L Nasonov8V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowObjective: to study the association of ultrasound (US) remission criteria with the clinical and laboratory indicators of inflammatory activity, functional status, and X-ray changes in patients with rheumatoid arthritis (RA) during tocilizumab (TCZ) therapy.Subjects and methods. The trial included 36 patients with RA (meeting the 1987 American College of Rheumatology (ACR) criteria) who had received TCZ for 6 months. The authors made a clinical and laboratory assessment of RA activity (DAS28-CRP, and SDAI), functional impairments (HAQ index) and US verification of wrist joint synovitis (a Voluson-i device, GE, 4-13-MHz linear transducer) at baseline and 6 months after therapy. No signs of grey-scale (B-mode) and power Doppler (PD) synovitis (B = 0; PD = 0) or minimal B-mode synovitis, and not more one PD hypervascular signal (В ≤1; PD ≤1) were arbitrarily taken as US remission criteria. Destruction changes were evaluated by hand and foot X-ray using the Sharp method modified by van der Heijde (SHS).Results. After 6 months of therapy, about 80% of the patients in clinical remission retained moderate or significant synovitis, as evidenced by US studies. There were no clinical differences in clinical activity indices and functional impairments between the patients who were and were not in US remission (p > 0.05). The 12-month follow-up SHS score was significantly higher with the preservation of 6-month therapy signs of B-mode synovitis and PD hypervascularization (of not more than one signal) than that in US remission (p < 0.05). There was no relationship of X-ray progression to the clinical and functional statuses (p > 0.05).Conclusion. Subclinical synovitis is observed even in clinical remission of RA. Destruction progression is significantlyrelated to synovitis persistence, as shown by ultrasonography.https://rsp.mediar-press.net/rsp/article/view/1335rheumatoid arthritis remissionjoint ultrasonographysubclinical synovitisx-ray destruction progressiontocilizumab |
| spellingShingle | Rita Aleksandrovna Osipyants D E Karateev E Yu Panasyuk G V Lukina A V Smirnov S I Glukhova E N Aleksandrova A V Volkov E L Nasonov EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY Научно-практическая ревматология rheumatoid arthritis remission joint ultrasonography subclinical synovitis x-ray destruction progression tocilizumab |
| title | EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_full | EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_fullStr | EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_full_unstemmed | EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_short | EVALUATION OF ULTRASOUND REMISSION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_sort | evaluation of ultrasound remission criteria in patients with rheumatoid arthritis during tocilizumab therapy |
| topic | rheumatoid arthritis remission joint ultrasonography subclinical synovitis x-ray destruction progression tocilizumab |
| url | https://rsp.mediar-press.net/rsp/article/view/1335 |
| work_keys_str_mv | AT ritaaleksandrovnaosipyants evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT dekarateev evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT eyupanasyuk evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT gvlukina evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT avsmirnov evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT siglukhova evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT enaleksandrova evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT avvolkov evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy AT elnasonov evaluationofultrasoundremissioncriteriainpatientswithrheumatoidarthritisduringtocilizumabtherapy |